

Short communication

Baseline susceptibility of primary HIV-2 to entry inhibitors

Pedro Borrego^{1,2}, Rita Calado^{1,2}, José M Marcelino³, Inês Bártolo^{1,2}, Cheila Rocha^{1,2}, Patrícia Cavaco-Silva², Manuela Doroana⁴, Francisco Antunes⁴, Fernando Maltez⁵, Umbelina Caixas⁶, Helena Barroso^{1,2}, Nuno Taveira^{1,2,7*}

¹URIA-CPM, Faculdade de Farmácia de Lisboa, Lisbon, Portugal

²Centro de Investigação Interdisciplinar Egas Moniz, Instituto Superior de Ciências da Saúde Egas Moniz, Monte de Caparica, Caparica, Portugal

³Unidade de Ensino e Investigação de Microbiologia Médica, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal

⁴Serviço de Doenças Infecciosas, Hospital de Santa Maria, Lisbon, Portugal

⁵Serviço de Doenças Infecciosas, Hospital de Curry Cabral, Lisbon, Portugal

⁶Serviço de Medicina 1.4, Hospital de S José and Faculdade de Ciências Médicas, FCM-Nova, Centro de Estudos de Doenças Crónicas, Lisbon, Portugal

⁷Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisbon, Portugal

*Corresponding author e-mail: ntaveira@ff.ul.pt

AU: Please confirm affiliations are now correct

Background: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.

Methods: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. The 50% inhibitory concentration (IC_{50}), 90% inhibitory concentration (IC_{90}) and dose-response curve slopes were determined for each drug.

Results: ENF and T-1249 were significantly less active on HIV-2 than on HIV-1 (211- and 2-fold, respectively). AMD3100 and TAK-779 inhibited HIV-2 and HIV-1 CXCR4 tropic (X4) and CCR5 tropic (R5) variants with similar IC_{50} and IC_{90} values. MVC, however, inhibited the replication

of R5 HIV-2 variants with significantly higher IC_{90} values (42.7 versus 9.7 nM; $P<0.0001$) and lower slope values (0.7 versus 1.3; $P<0.0001$) than HIV-1. HIV-2 R5 variants derived from AIDS patients were significantly less sensitive to MVC than variants from asymptomatic patients, this being inversely correlated with the absolute number of CD4⁺ T-cells.

Conclusions: T-1249 is a potent inhibitor of HIV-2 replication indicating that new fusion inhibitors might be useful to treat HIV-2 infection. Coreceptor antagonists TAK-779 and AMD3100 are also potent inhibitors of HIV-2 replication. The reduced sensitivity of R5 variants to MVC, especially in severely immunodeficient patients, indicates that the treatment of HIV-2-infected patients with MVC might require higher dosages than those used in HIV-1 patients, and should be adjusted to the disease stage.

Introduction

HIV-2 affects an estimated 1–2 million individuals worldwide and leads to AIDS and death, albeit at a slower pace when compared to HIV-1. All currently available anti-retroviral drugs were specifically designed to inhibit HIV-1 entry and replication. Consequently, some drug classes are not active on HIV-2 (that is, non-nucleoside reverse transcriptase and fusion inhibitors) and virological and immunological responses to treatment regimens incorporating active drugs are usually poorer in HIV-2 patients [1].

The envelope glycoproteins of HIV-1 and HIV-2 are markedly different at the amino acid sequence level and at the structural and functional levels. In contrast to HIV-1, HIV-2 may enter cells without binding to CD4, and by using multiple alternative coreceptors besides CCR5 and CXCR4 [2,3]. This suggests that maraviroc (MVC), a CCR5 antagonist, might also have limited activity against HIV-2. Currently, there is no information concerning the *in vitro* susceptibility of HIV-2 primary isolates to MVC,

enfuvirtide (ENF) or any other entry inhibitor. In the absence of formal clinical trials, *in vitro* evaluation of the baseline susceptibility of HIV-2 primary isolates to MVC is crucial to assess the potential clinical value of this drug in HIV-2 therapy [4]. Here we have analysed the susceptibility of HIV-2 primary isolates obtained from asymptomatic and AIDS patients to the fusion inhibitors ENF and T-1249 and to the coreceptor antagonists AMD3100, TAK-779 and MVC.

Methods

Primary isolates were obtained from HIV-2-infected Portuguese patients and, for comparison, from HIV-1-infected Angolan patients, all naive to therapy with entry inhibitors, by cocultivation with peripheral blood mononuclear cells from seronegative subjects (Table 1) [5]. Virus genotyping was performed by phylogenetic analysis using C2-V3-C3 (HIV-2) or gp41 (HIV-1) *env* sequences. GenBank accession numbers for newly derived sequences are HQ738345–HQ738350 for HIV-2 and HQ738338–HQ738344 for HIV-1.

CCR5 and CXCR4 tropism was determined using a single-round viral infectivity assay performed with TZM-bl reporter cells (CD4⁺, CCR5⁺ and CXCR4⁺) in the presence of excessive amounts of the CCR5 antagonist TAK-779 (10 μ M) and/or of the CXCR4 antagonist AMD3100 (1.2 μ M), as previously described [6]. The 50% inhibitory concentration (IC₅₀), 90% inhibitory concentration (IC₉₀) and dose–response curve slopes (Hill slopes) of ENF and T-1249 (fusion inhibitors) and AMD3100, TAK-779 and MVC (coreceptor antagonists) were determined on the newly derived panel of isolates (200 \times 50% tissue culture infective dose for each virus) using also the TZM-bl reporter cell assay. IC₅₀, IC₉₀ and Hill slopes were estimated by the sigmoidal dose–response (variable slope) equation in Prism version 4.0c for Macintosh (GraphPad Software, San Diego, CA, USA). Prism was also used for statistical analyses (P -value <0.05).

Results

Genotypic and phenotypic characterization of virus isolates

A total of 19 new HIV-2 primary isolates were used in this study, all belonging to group A (Table 1 and Additional file 1). Overall, 10 were CCR5 tropic (R5 isolates), 8 CXCR4 tropic (X4 isolates) and 1 used both coreceptors (dual/mixed population). The seven new HIV-1 primary isolates were all R5 and their genotypes were distributed as follows: subtype G (1 isolate), J (2 isolates) and CRF02_AG (1 isolate); 3 isolates were untypable (Table 1 and Additional file 2).

Antiviral activity of coreceptor antagonists

AMD3100 and TAK-779 inhibited the replication of HIV-1 and HIV-2 with similar IC₅₀, IC₉₀ and slope values (Tables 1 and 2). MVC also inhibited the replication of HIV-2 and HIV-1 R5 variants with similar IC₅₀ values (Table 1); for HIV-1, the IC₅₀s were similar to previously reported values (range 0.1–4.5 nM; Table 1) [7]. However, MVC inhibited the replication of R5 HIV-2 variants with significantly higher IC₉₀ values (42.7 versus 9.7 nM; $P<0.0001$) and lower slope values (0.7 versus 1.3; $P<0.0001$) than HIV-1 (Figure 1A and Table 2). R5 variants isolated from HIV-1 patients after AIDS diagnosis have reduced sensitivity to TAK-779 as compared to R5 variants isolated at the asymptomatic stage [8,9]. Strikingly, we also found a strong and significant negative correlation between HIV-2 sensitivity to MVC (as determined by the IC₅₀) and CD4⁺ T-cell counts at the time of virus isolation (Spearman's $r=-0.831$; $P=0.008$; Figure 1B). Consistent with this, isolates from AIDS patients were significantly less sensitive to MVC (that is, their IC₅₀s were significantly higher) than isolates from asymptomatic patients (Figure 1C). A similar tendency was observed for TAK-779 (Additional file 3). In all, these results demonstrate that HIV-2 R5 variants have lower sensitivity to MVC than HIV-1 and suggest that resistance of these variants to MVC increases as disease progresses [8,9].

Antiviral activity of fusion inhibitors

In this study, ENF was 211-fold less active against primary isolates of HIV-2 than against HIV-1 (mean IC₅₀ 281.5 versus 1.2 nM; $P<0.0001$; Figure 1D and Table 2), confirming and extending previous results based on lab adapted isolates [10]. Interestingly, with one exception, all HIV-1 primary isolates exhibited high sensitivity to ENF (Table 1). Sequencing analysis showed that these isolates carried the N42S polymorphism in the gp41 glycoprotein, whereas the less sensitive strain did not (data not shown). This polymorphism, which is more prevalent in several non-B subtypes and recombinant forms than in subtype B, has previously been associated with higher sensitivity to ENF both in B and non-B HIV-1 subtypes [11].

In contrast to ENF, T-1249 was active on HIV-2, although at higher concentrations than on HIV-1 (IC₅₀ 4.3 versus 2.0 nM; $P<0.0001$). Moreover, T-1249 was more active on X4 than on R5 isolates both in HIV-1 (IC₅₀ 0.6 versus 2.9 nM; $P<0.0001$) and HIV-2 (IC₅₀ 3.2 versus 6.1 nM; $P=0.0005$).

Discussion

We have demonstrated that MVC inhibits the replication of R5 HIV-2 variants with significantly higher

[AU: Ok?
Correction was
partially cut off]

AU: OK?

Table 1. Clinical characterization of HIV patients and primary isolates including their susceptibility to different entry inhibitors

solates ^b	CD4 ⁺ T-cell count at study entry, cells/ μ l	HIV RNA, copies/ml	Antiretroviral therapy	Genetic forms ^c	Coreceptor use	Antiviral activity ^a											
						AMD3100, nM		TAK-775, nM		Maraviroc, nM		Enfuvirtide, nM		T-1249, nM			
						IC ₅₀	IC ₉₀	IC ₅₀	IC ₉₀	IC ₅₀	IC ₉₀	IC ₅₀	IC ₉₀	IC ₅₀	IC ₉₀		
HIV-1	33AOHDC249	NA	No	U	R5	-	-	6.1	173.0	1.0	6.1	78.8	1,285.3	8.0	13.2		
	33AOHDC250	NA	No	J	R5	-	-	8.1	7,516.2	2.4	9.7	0.4	15.7	1.9	8.7		
	33AOHDC251	NA	No	U	R5	-	-	5.7	23,388.4	1.5	9.2	1.3	170.2	1.8	43.6		
	33AOHDC252	NA	No	U	R5	-	-	153.5	24,434.3	4.7	48.5	3.7	23.5	2.6	8.0		
	33AOHDC253	NA	No	J	R5	-	-	15.7	423.6	1.4	4.5	0.1	2.0	1.4	8.6		
	01PTHDECJN	1,003	<400	CRF02_AG	R5	-	-	178.4	5,942.9	2.7	11.9	0.7	132.1	1.6	6.7		
	00PTHDEEBB	409	2,742,788	G	R5	-	-	2.6	2,844.5	0.8	3.8	1.5	33.6	5.5	78.5		
	NI4-3	-	-	B	X4	0.9	6.0	-	-	-	-	5.0	178.6	0.6	1.0		
	GG3.1	-	-	B	X4	5.2	29.2	-	-	-	-	0.1	0.5	0.4	6.9		
	HIV-2	03PTHCC1	308	<200	A	R5	-	-	0.6	1,219.0	0.9	4.8	35.6	877.0	5.1	49.3	
03PTHCC6		615	<200	A	R5	-	-	10.1	2,301.4	0.9	32.3	661.1	2,192.8	8.4	74.1		
03PTHCC7		144	<200	A	R5	-	-	16.2	3,581.0	2.9	28.9	549.1	2,138.0	7.3	12.6		
03PTHCC12		66	<200	A	R5	-	-	45.1	7,030.7	3.8	78.7	2,857.0	32,062.7	6.3	36.6		
03PTHCC17		367	<200	A	R5	-	-	3.0	55,080.8	0.9	27.9	138.4	2,162.7	2.5	40.3		
03PTHCC19		175	NA	A	R5	-	-	128.3	167,880.4	4.3	81.5	250.0	1,729.8	7.2	24.6		
00PTHDECT		2,919	1,355	A	R5	-	-	24.8	3,741.1	1.6	61.1	109.3	881.0	2.3	24.4		
10PTHJIG		164	4,257	A	R5	-	-	121.8	8,128.3	5.5	108.6	586.3	14,092.9	21.9	412.1		
03PTHSM2		275	<200	A	R5	-	-	8.8	15,922.1	2.4	53.1	114.0	4,375.2	3.4	61.9		
10PTHSMNC		231	<200	A	R5	-	-	57.4	3,396.3	2.2	40.1	265.4	3,507.5	8.9	71.3		
10PTHSMAC		40	1,793	A	D/M	3.2	17.9	0.7	29,922.6	116.0	30,903.0	125.2	1,458.8	1.5	45.6		
ROD		-	-	A	X4	1.0	16.1	-	-	-	-	76.1	3,380.6	9.1	174.6		
03PTHCC10		48	<200	A	X4	3.6	78.3	-	-	-	-	293.6	3,047.9	2.4	12.4		
00PTHCC20		1,033	<200	A	X4	1.9	17.5	-	-	-	-	151.3	1,422.3	0.9	8.4		
03PTHCC20		78	<200	A	X4	2.0	18.6	-	-	-	-	362.7	3,548.1	1.9	10.9		
03PTHDECT		209	20,968	A	X4	1.6	20.7	-	-	-	-	373.4	5,520.8	2.1	32.1		
01PTHDESC		44	1,250	A	X4	4.0	32.7	-	-	-	-	241.5	3,672.8	4.9	49.1		
03PTHSM9	15	<200	A	X4	4.2	27.7	-	-	-	-	1,281.0	6,729.8	7.0	12.6			
04PTHSM10	265	4,792	A	X4	3.6	47.1	-	-	-	-	293.6	3,047.9	6.7	24.3			
10PTHSMAC	177	<200	A	X4	3.0	20.9	-	-	-	-	167.3	952.8	1.7	12.0			

^aThe 50% inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) best-fit values were inferred from sigmoidal dose-response (variable slope) curves and represent geometric mean values of two independent experiments performed in duplicate wells; AMD3100 was only tested against CXCR4 tropic (X4) isolates, while TAK-775 and maraviroc were tested against CCR5 tropic (R5) isolates. ^bLab-adapted reference strains NL4-3 (HIV-1), SG3.1 (HIV-1) and ROD (HIV-2) were obtained by transfection of 293T cells with pNL4-3 (HIV-1), pSG3.1 (HIV-1) or pROD10 (HIV-2) plasmids. ^cUntypable (U) HIV-1 isolates included 93AOHDC249 and 93AOHDC252 sequences, which are basal to subtypes 19_cpx and 37_cpx and the 93AOHDC251 sequence, which is basal to subtype H (Additional file 2). D/M, dual/mixed viral population using CCR5 and CXCR4 coreceptors; NA, not available.

Table 2. Comparison of antiviral activities of the different entry inhibitors on HIV-1 and HIV-2 primary isolates

Parameter ^a	HIV-1	HIV-2 ^b	P-value ^c
AMD3100	–	–	–
Patients, <i>n</i>	2	9	–
IC ₅₀ , nM	2.1 (1.1, 3.8)	2.6 (2.2, 3.0)	0.288
IC ₉₀ , nM	16.7 (4.4, 62.8)	29.0 (20.8, 40.5)	0.213
Hill slope	1.0 (0.5, 1.6)	0.9 (0.8, 1.0)	0.391
TAK-779	–	–	–
Patients, <i>n</i>	7	10	–
IC ₅₀ , nM	23.3 (12.0, 45.4)	18.9 (11.8, 30.3)	0.595
IC ₉₀ , nM	5,200.0 (1,161.4, 23,334.6)	11,587.8 (3,899.4, 34,514.4)	0.379
Hill slope	0.4 (0.3, 0.5)	0.3 (0.3, 0.4)	0.237
Maraviroc	–	–	–
Patients, <i>n</i>	7	10	–
IC ₅₀ , nM	1.7 (1.4, 2.2)	2.1 (1.7, 2.6)	0.201
IC ₉₀ , nM	9.7 (6.6, 14.4)	42.7 (26.6, 68.4)	<0.0001
Hill slope	1.3 (1, 1.6)	0.7 (0.6, 0.8)	<0.0001
Enfuvirtide	–	–	–
Patients, <i>n</i>	9	20	–
IC ₅₀ , nM	1.2 (0.7, 2.2)	281.5 (223.2, 354.9)	<0.0001
IC ₉₀ , nM	95.9 (26.3, 350.8)	3,881.5 (2,393.3, 6,280.6)	<0.0001
Hill slope	0.5 (0.4, 0.6)	0.8 (0.7, 1)	0.001
T-1249	–	–	–
Patients, <i>n</i>	9	20	–
IC ₅₀ , nM	2.0 (1.4, 2.8)	4.3 (3.6, 5.2)	<0.0001
IC ₉₀ , nM	14.3 (6.9, 29.5)	40.6 (28.1, 58.5)	0.006
Hill slope	1.1 (0.8, 1.4)	1 (0.8, 1.1)	0.426

Data are mean (95% CI). ^aThe 50% inhibitory concentration (IC₅₀), the 90% inhibitory concentration (IC₉₀) and slope best-fit values were inferred from sigmoidal dose-response (variable slope) curves adjusted to combined results of HIV-1 and HIV-2 isolates. ^bEstimates for AMD3100, TAK-779 and maraviroc did not include the HIV-2 10PTHSMK isolate, a virus with dual/mixed tropism. ^cP-value for comparison of best-fit values between HIV-1 and HIV-2, using the F test.

IC_{90s} and lower slope values than HIV-1 indicating that higher dosages of MVC might be required for the treatment of HIV-2-infected patients [12,13]. So far, MVC use in HIV-2 infection was reported on only two occasions with uncertain results [14,15]. Clinical trials are therefore needed to determine if the MVC dosages recommended in HIV-1 infection are also effective for HIV-2 infection. This may prevent the administration of subtherapeutic dosages that favour the selection of X4 variants which, in HIV-2, have been associated not only with CD4 depletion and disease progression [2], but also with resistance to neutralization [16].


Similarly to previous results obtained with RANTES for HIV-2 [17] and with TAK-779 and C-C chemokines for HIV-1 [8,9], MVC inhibits the replication of R5 HIV-2 variants isolated from AIDS patients with significantly higher IC_{50s} than R5 variants isolated from asymptomatic patients, this being inversely associated with the number of CD4⁺ T-cells. In HIV-2-infected patients, CD4 depletion and higher immune activation are also closely associated with an increased frequency of memory CD4⁺ T-cells expressing CCR5, the preferential target cells of this virus [18]. Hence, these results suggest that in HIV-2-infected patients MVC dosage

may need to be adjusted according to the number of CD4⁺ T-cells (higher dosage in severely immunodeficient patients and lower dosage in asymptomatic patients). Increased MVC resistance of late stage disease R5 variants might be explained by increased affinity for CCR5 [19] and/or an enhanced viral infectivity and replicative capacity [8,19]. Alternatively, these R5 variants may be evolutionary intermediates toward X4 use [8,17].

The reduced activity of ENF on primary HIV-2 isolates provides definitive evidence that ENF is not useful for HIV-2 therapy. The low activity of ENF in HIV-2 is probably related to the high genetic variability between HIV-1 and HIV-2 in the HR1 and HR2 domains in the gp41 glycoprotein [10,20]. By contrast, T-1249, a second-generation fusion inhibitor available only for research use was highly active on both HIV-1 and HIV-2 indicating that new fusion inhibitors (peptides or small-molecules) might be useful to treat HIV-2 infection.

In summary, primary isolates of HIV-1 and HIV-2 with X4 or R5 tropism have similar sensitivities to AMD3100 and TAK-779, respectively. However, significantly higher IC_{90s} of MVC are required to inhibit

Figure 1. HIV-1 and HIV-2 susceptibility to clinically available fusion inhibitors



Representative dose-response curves for HIV-1 and HIV-2 with (A) maraviroc and (B) enfuvirtide. Data points represent the mean of results obtained on HIV-1 and HIV-2 isolates and bars represent the 95% CI of the mean. Sigmoidal dose-response (variable slope) curves were adjusted to these data points; dashed lines represent the 95% confidence band of the best-fit curve. (C) Scatter plot of maraviroc 50% inhibitory concentrations (IC_{50}) with the CD4⁺ T-cell counts at the time of virus isolation in each HIV-2 patient infected with a CCR5 coreceptor tropism (R5) variant. Parameters from non-parametric correlation and linear regression analysis are shown. Isolate 00PTHDECT was excluded from this analysis since it was isolated from a child and therefore only CD4⁺ T-cell percentage and not absolute CD4⁺ T-cell counts should be considered. (D) Distribution of maraviroc IC_{50} (closed circles) and 90% inhibitory concentration (IC_{90} ; open circles) values according to two arbitrary levels of CD4⁺ T-cells: <200 cells/ μ l, which is an AIDS-defining condition, and >200 cells/ μ l. Isolate 00PTHDECT was also excluded from this analysis. P -value for comparison of medians was determined using the non-parametric Mann-Whitney U test. D/M, dual/mixed viral population using CCR5 and CXCR4 coreceptors; X4, CXCR4 tropism.

AU: OK?

replication of HIV-2 R5 variants than HIV-1 variants. Additionally, the sensitivity of HIV-2 R5 variants to this drug is inversely related with CD4⁺ T-cell counts at time of virus isolation. If MVC is to be used in HIV-2 patients, clinical trials should be performed to fully evaluate the clinical efficacy of this drug in HIV-2 infection and determine the best therapeutic dosage in early- and late-stage disease. Because X4 HIV-2 variants and dual/mixed HIV-2 populations are totally or partially resistant to MVC, coreceptor

tropism should be determined before initiation of MVC therapy in HIV-2-infected patients. To this end, genotypic tropism assays, possibly based on the sequence of the V3 loop [2], should be developed to facilitate tropism assignment. Once used regularly in HIV-2 patients, the effect of MVC in the phenotypic evolution of this virus *in vivo* should be fully investigated as MVC has the potential to select for HIV-2 X4 variants that are associated with poor disease prognosis.

Acknowledgements

This work was supported by Fundação para a Ciência e Tecnologia (grant number PTDCSAU-FCF6767/2006), Portugal, and by the Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN), from the European Union. PB, RC, IB and CR are supported by PhD grants from Fundação para a Ciência e Tecnologia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: bicyclam JM-2987 (hydrobromide salt of AMD-3100), pNL4-3 from Malcolm Martin, pSG3.1 from Sajal Ghosh, T-20 (ENF, fusion inhibitor) from Roche, TAK-779 from Takeda Chemical Industries, TZM-bl from John C Kappes, Xiaoyun Wu, and Tranzyme, Inc. pROD10 plasmid was a kind gift from Keith Peden. Trimeris Inc (NC, USA) and Pfizer Inc (NY, USA) provided T-1249 and MVC, respectively.

AU: OK?

Disclosure statement

The authors declare no competing interests.

Additional files

Additional file 1: Supplementary figure S1 illustrating genotyping of HIV-2 by maximum-likelihood phylogenetic analysis can be found at www.intmedpress.com/XXX

Additional file 2: Supplementary figure S2 illustrating genotyping of HIV-1 by maximum-likelihood phylogenetic analysis can be found at www.intmedpress.com/XXX

Additional file 3: Supplementary figure S3 illustrating the association between HIV-2 susceptibility to TAK-779 and the immunodeficiency degree of HIV-2 patients can be found at www.intmedpress.com/XXX

References

1. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. *Antimicrob Agents Chemother* 2009; 53:3611–3619.
2. Shi Y, Brandin E, Vincic E, et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. *J Gen Virol* 2005; 86:3385–3396.
3. Reeves JD, Hibbitts S, Simmons G, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism *in vivo*. *J Virol* 1999; 73:7795–7804.
4. Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. *Aids Res Treat* 2011; 2011:463704.
5. Cavaco-Silva P, Taveira NC, Rosado L, et al. Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. *J Virol* 1998; 72:3418–3422.
6. Davis KL, Bibollet-Ruche F, Li H, et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. *J Virol* 2009; 83:1240–1259.
7. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. *Antimicrob Agents Chemother* 2005; 49:4721–4732.
8. Repits J, Oberg M, Esbjornsson J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. *J Gen Virol* 2005; 86:2859–2869.
9. Scarlatti G, Tresoldi E, Bjornald A, et al. *In vivo* evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. *Nat Med* 1997; 3:1259–1265.
10. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. *Antivir Ther* 2004; 9:57–65.
11. Melby T, Sista P, DeMasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. *AIDS Res Hum Retroviruses* 2006; 22:375–385.
12. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. *Nat Med* 2008; 14:762–766.
13. Sampah ME, Shen L, Jilek BL, Siliciano RF. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. *Proc Natl Acad Sci U S A* 2011; 108:7613–7618.
14. Stegmann S, Manea ME, Charpentier C, et al. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. *J Clin Virol* 2010; 47:79–81.
15. Armstrong-James D, Stebbing J, Scourfield A, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. *Antiviral Res* 2010; 86:224–226.
16. Marcelino JM, Borrego P, Rocha C, et al. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. *J Virol* 2010; 84:12429–12436.
17. Blaak H, Boers PH, van der Ende ME, Schuitemaker H, Osterhaus AD. CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variants. *AIDS Res Hum Retroviruses* 2008; 24:473–484.
18. Soares R, Foxall R, Albuquerque A, et al. Increased frequency of circulating CCR5⁺ CD4⁺ T cells in human immunodeficiency virus type 2 infection. *J Virol* 2006; 80:12425–12429.
19. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. *Proc Natl Acad Sci U S A* 2002; 99:16249–16254.
20. Poveda E, Rodes B, Toro C, Soriano V. Are fusion inhibitors active against all HIV variants? *AIDS Res Hum Retroviruses* 2004; 20:347–348.

Accepted 27 July 2011; published online XX XXXX 2011